: Phase 3 readouts for retatrutide (Triumph-1, -2, and -3 trials) are due mid-2026.
: Widely considered a top pick for 2026 due to its dominance in Cystic Fibrosis and the rollout of Casgevy . best biotech stocks to buy now
The biotech sector in April 2026 is characterized by a "Pivot to Growth," driven by breakthroughs in , CRISPR gene editing , and AI-integrated drug discovery . Investors are shifting focus toward established leaders with robust pipelines and emerging mid-caps reaching critical clinical milestones. Top Large-Cap "Strong Buy" Leaders : Phase 3 readouts for retatrutide (Triumph-1, -2,
: Leading the obesity market with Zepbound ; it is expected to seek FDA approval for its oral GLP-1 (orforglipron) in 2026. Investors are shifting focus toward established leaders with
: Gaining traction after beating earnings and listing directly on the Nasdaq Global Select Market on April 20, 2026.